Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERC1
REST API REST API
Homo sapiens
ERC1 is differentially expressed in 267 experiments: 126 organism parts: cerebellum, dorsal root ganglion, ... (124 more);, 136 disease states: normal, myeloma, ... (134 more);, 80 cell types 379 cell lines 37 compound treatments and 68 other conditions.
Synonyms CAST2, ELKS, KIAA1081, RAB6IP2, MGC12974
Orthologs Erc1 (Mus musculus)   ERC1 (Gallus gallus)   ERC1 (Bos taurus)   ENSCING00000000409 (Ciona intestinalis)   ENSCING00000017369 (Ciona intestinalis)   ERC1 (2 of 3) (Danio rerio)   Erc1 (Rattus norvegicus)   erc1a (Danio rerio)   erc1b (Danio rerio)   erc1 (Xenopus laevis)   ENSCAFG00000015874 (Canis familiaris)   ENSCAFG00000025245 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, cytoplasm, retrograde transport, endosome to Golgi, membrane, Golgi membrane, Golgi apparatus, presynaptic membrane, Rab GTPase binding, multicellular organismal development, positive regulation of NF-kappaB transcription factor activity, PDZ domain binding, protein transport, positive regulation of anti-apoptosis, leucine zipper domain binding, IkappaB kinase complex, I-kappaB phosphorylation
InterPro Term CAZ_cplx_RIM-bd_prot, Rab-bd_FIP-RBD
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY
UniProt Accession Q8IUD2, F5GZU8, F5H185, F5H327
Search EB-eye ENSG00000082805
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-GEOD-7224, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
373 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-MEXP-750, E-GEOD-4219, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-5099, E-GEOD-22373
human embryonic stem cell
1
2
E-GEOD-18265, E-GEOD-18147, E-GEOD-20033
stromal cell
1
2
E-GEOD-1460, E-GEOD-10797, E-MEXP-2034
nucleus pulposus
1
E-MEXP-2488
induced pluripotent stem cell
1
E-GEOD-18147
leydig cell
1
E-MTAB-25
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-MEXP-1121, ... (45 experiments)

Factor Value U/D Experiments
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
Follicular Carcinoma
1
E-MEXP-2442
Papillary Carcinoma
1
E-MEXP-2442
monoclonal gammopathy of unknown significance
1
E-MTAB-62
130 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
hydroxyurea
2
E-GEOD-6431, E-GEOD-571
none
3
4
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-GEOD-5099, E-TABM-868, ... (7 experiments)
sapphyrin PCI-2054
1
E-GEOD-6400
NaOH
1
1
E-MEXP-2590
placebo
1
E-MEXP-1335
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-20499, E-GEOD-21589, E-GEOD-16363, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-GEOD-21612, E-TABM-127, E-GEOD-20540, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.296 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM